PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 377630

Decrease in the graft rejection rate and improvement in survival after marrow transplantation for severe aplastic anemia.

R Storb
View original source ↗Export metadata ↓

Abstract

The source did not provide an abstract. Follow the original record for more information.

Explore related subjects

Anemia, AplasticBone Marrow TransplantationCyclophosphamideGraft RejectionHumansImmunosuppression TherapyPrognosisJournal ArticleResearch Support, U.S. Gov't, P.H.S.

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R Storb. 1979. Decrease in the graft rejection rate and improvement in survival after marrow transplantation for severe aplastic anemia.. https://pubmed.ncbi.nlm.nih.gov/377630/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1992

The use of colony-stimulating factors in primary hematologic disorders.

BACKGROUND: The cloning of the human colony-stimulating factors (CSF), granulocyte CSF, granulocyte-macrophage CSF, and interleukin-3 has led to their use in a variety of clinical settings. RESULTS: These CSF have been used successfully to raise neutrophil counts and prevent or control infection in patients with neutropenia due to primary hematologic disorders. Their effects on platelet and erythrocyte counts have been modest; occasional patients have multilineage improvement in hematopoiesis. CONCLUSIONS: The CSF can be given for several months at effective and tolerable doses. Their long-term efficacies and toxicities remain to be elucidated, and the optimal dose and dosing schedule to be used for each indication are not defined currently. Although the CSF can improve hematopoiesis in patients with primary hematologic disorders, they are not curative.

Anemia, Aplastic↗